Evidence map›Paper›PMID 37802268›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2024

Progression of Pediatric Crohn's Disease Is Associated With Anti-Tumor Necrosis Factor Timing and Body Mass Index Z-Score Normalization.

Duke Geem, David Hercules, Ranjit S Pelia, Suresh Venkateswaran, Anne Griffiths, Joshua D Noe, Jennifer L Dotson, Scott Snapper, Shervin Rabizadeh, Joel R Rosh and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Pediatric stricturing Crohn's disease.World journal of gastroenterology · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Duke GeemDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Atlanta, Georgia.
David HerculesDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
Ranjit S PeliaDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
Suresh VenkateswaranDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
Anne GriffithsDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Joshua D NoeGastroenterology, Hepatology, and Nutrition, Medical College of Wisconsin, Milwaukee, Wisconsin.
Jennifer L DotsonDepartment of Pediatric Gastroenterology, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, Ohio.
Scott SnapperDepartment of Gastroenterology and Nutrition, Boston Children's Hospital, Boston, Massachusetts.
Shervin RabizadehDepartment of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California.
Joel R RoshDepartment of Pediatrics, Goryeb Children's Hospital, Morristown, New Jersey.
Robert N BaldassanoDepartment of Pediatrics, University of Pennsylvania, Philadelphia, Pennsylvania.
James F MarkowitzDepartment of Pediatrics, Northwell Health, New York, New York.
Thomas D WaltersDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Ashwin AnanthakrishnanDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Garima SharmaDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia.
Lee A DensonDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Jeffrey S HyamsDivision of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children's Medical Center, Hartford, Connecticut.
Subra KugathasanDivision of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia; Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's Healthcare of Atlanta, Atlanta, Georgia. Electronic address: skugath@emory.edu.

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
Research Training in Translational Gastroenterology and HepatologyT32DK108735 · NIDDK · EMORY UNIVERSITY · PI SUBRA KUGATHASAN · 2016 to 2026
$2.6M
NIDDK NIH HHS P30 DK078392NIDDK NIH HHS T32 DK108735
6 · The paper itself

Abstract

BACKGROUND &

aimsThe evolution of complicated pediatric Crohn's disease (CD) in the era of anti-tumor necrosis factor (aTNF) therapy continues to be described. Because CD progresses from inflammatory to stricturing (B2) and penetrating (B3) disease behaviors in a subset of patients, we aimed to understand the risk of developing complicated disease behavior or undergoing surgery in relation to aTNF timing and body mass index z-score (BMIz) normalization.

methodsMulticenter, 5-year longitudinal data from 1075 newly diagnosed CD patients were analyzed. Descriptive statistics, univariate and stepwise multivariate Cox proportional hazard regression (CPHR), and log-rank analyses were performed for risk of surgery and complicated disease behaviors. Differential gene expression from ileal bulk RNA sequencing was correlated with outcomes.

resultsStricturing complications had the largest increase: from 2.98% to 10.60% over 5 years. Multivariate CPHR showed aTNF exposure within 3 months from diagnosis (hazard ratio [HR], 0.33; 95% CI, 0.15-0.71) and baseline L2 disease (HR, 0.29; 95% CI, 0.09-0.92) to be associated with reduced B1 to B2 progression. For children with a low BMIz at diagnosis (n = 294), multivariate CPHR showed BMIz normalization within 6 months of diagnosis (HR, 0.47; 95% CI, 0.26-0.85) and 5-aminosalicyclic acid exposure (HR, 0.32; 95% CI, 0.13-0.81) were associated with a decreased risk for surgery while B2 (HR, 4.20; 95% CI, 1.66-10.65) and B2+B3 (HR, 8.24; 95% CI, 1.08-62.83) at diagnosis increased surgery risk. Patients without BMIz normalization were enriched for genes in cytokine production and inflammation.

conclusionsaTNF exposure up to 3 months from diagnosis may reduce B2 progression. In addition, lack of BMIz normalization within 6 months of diagnosis is associated with increased surgery risk and a proinflammatory transcriptomic profile.

Indexed as

Crohn DiseaseBody Mass IndexChildConstriction, PathologicDisease ProgressionHumansNecrosisRetrospective StudiesRisk FactorsTumor Necrosis Factor-alphaTumor Necrosis Factor-alphaAnti–Tumor Necrosis FactorCrohn's DiseaseInflammatory Bowel DiseaseNatural HistoryPediatrics

Identifiers

PMID37802268
PMCPMC11839178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.